RFK Jr. is declaring war on chronic illness, which, if he succeeds, will not only make us healthier but will also cut down ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Tori Allen says she's thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more people are using to treat diabetes or lose weight.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

These stocks have climbed more than 80% and 200% over the past three years. But demand for their products and potential ...

Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...